Sunday, November 16, 2025
DIGESTWIRE
Contribute
CONTACT US
  • Home
  • World
  • UK
  • US
  • Breaking News
  • Technology
  • Entertainment
  • Health Care
  • Business
  • Sports
    • Sports
    • Cricket
    • Football
  • Defense
  • Crypto
    • Crypto News
    • Crypto Calculator
    • Coins Marketcap
    • Top Gainers and Loser of the day
    • Crypto Exchanges
  • Politics
  • Opinion
  • Blog
  • Founders
No Result
View All Result
  • Home
  • World
  • UK
  • US
  • Breaking News
  • Technology
  • Entertainment
  • Health Care
  • Business
  • Sports
    • Sports
    • Cricket
    • Football
  • Defense
  • Crypto
    • Crypto News
    • Crypto Calculator
    • Coins Marketcap
    • Top Gainers and Loser of the day
    • Crypto Exchanges
  • Politics
  • Opinion
  • Blog
  • Founders
No Result
View All Result
DIGESTWIRE
No Result
View All Result
Home Technology

Experimental drug extends the lifespan of mice – and could work on humans, scientists say

by DigestWire member
July 17, 2024
in Technology
0
Experimental drug extends the lifespan of mice – and could work on humans, scientists say
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter

An experimental drug that extends the lifespan of mice by 25% could also work in humans, according to the scientist who ran the trials.

The treatment – an injection of an antibody called anti-IL-11 that was given to the mice when they were ‘middle-aged’ – reduced deaths from cancer.

It also lowered the incidence of diseases caused by fibrosis, chronic inflammation and poor metabolism, which are the hallmarks of ageing.

Professor Stuart Cook, a senior scientist on the study, said: “These findings are very exciting.

“While these findings are only in mice, it raises the tantalising possibility that the drugs could have a similar effect in elderly humans.

“The treated mice had fewer cancers, and were free from the usual signs of ageing and frailty, but we also saw reduced muscle wasting and improvement in muscle strength.

“In other words, the old mice receiving anti-IL-11 were healthier.”

Videos released by the scientists show untreated mice had greying patches on their fur, with hair loss and weight gain.

But those receiving the injection had glossy coats and were more active.

The researchers, from the Medical Research Council Laboratory of Medical Science (MRC LMS), Imperial College London and Duke-NUS Medical School in Singapore, gave the mice the antibody injection when they were 75 weeks old – equivalent to a human age of 55 years.

The mice went on to live to an average of 155 weeks, 35 weeks longer than mice who were not treated, according to results published in the journal Nature.

The drug appeared to have very few side effects.

“Previously proposed life-extending drugs and treatments have either had poor side-effect profiles, or don’t work in both sexes, or could extend life, but not healthy life – however this does not appear to be the case for IL-11,” Professor Cook said.

The antibody blocked the action of the IL-11 protein, which is thought to play a role in the ageing of cells and body tissues – in humans as well as mice.

Keep up with all the latest news from the UK and around the world by following Sky News

Professor Cook said: “The IL-11 gene activity increases in all tissues in the mouse with age.

“When it gets turned on it causes multimorbidity, which is diseases of ageing and loss of function across the whole body, ranging from eyesight to hearing, from muscle to hair, and from the pump function of the heart to the kidneys.”

Scientists have been trying to find a way of slowing the ageing process in the body so people can remain healthier for longer.

Read more from Sky News:
Prison to temporarily close after radioactive gas found
Rare video of uncontacted Amazon tribe
Paris mayor swims in River Seine to prove it’s clean

Be the first to get Breaking News

Install the Sky News app for free

Older people tend to have multiple diseases related to their age, with significant impacts on their quality of life as well as costs to the NHS.

A diabetes drug called metformin has also shown promising results in early studies.

There have also been experiments with severe calorie restriction in people.

However, other scientists are sceptical of ‘treating’ ageing.

Ilaria Bellantuono, professor of musculoskeletal ageing at the University of Sheffield, said: “The problem with all these interventions is that we do not have evidence in patients.

“Although trials are under way in the USA, there are scientific hurdles to overcome to use these interventions in patients, such as understanding who is at risk of frailty and would benefit from the intervention.

“It is unthinkable to treat every 50-year-old for the rest of their life. Every drug has side effects and there is a cost associated with it.”

Read Entire Article
Tags: SkynewsTechnology
Share30Tweet19
Next Post
Coons: Too soon to fire Secret Service chief

Coons: Too soon to fire Secret Service chief

Donald Trump’s Third Presidential Life

Donald Trump's Third Presidential Life

Broken Windows Policing Returns to Philadelphia

Broken Windows Policing Returns to Philadelphia

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

I agree to the Terms & Conditions and Privacy Policy.

No Result
View All Result
Coins MarketCap Live Updates Coins MarketCap Live Updates Coins MarketCap Live Updates
ADVERTISEMENT

Highlights

Nearly 70 schools to close in Australia over fears of asbestos in play sand

Arrest over deadly car blast in New Delhi

Tom Lee Reveals Why Bitcoin, Ethereum And XRP Are Still Crashing

XRP Is Not Bitcoin Or Ethereum, Says Canary CEO As XRPC ETF Launches

Altcoin News: Is It Time To Sell XRP And Buy Zcash?

Detroit Lions @ Philadelphia Eagles: Preview, prediction and odds

Trending

‘Job’s far from done’ – Conrad eyes series win
Cricket

‘Job’s far from done’ – Conrad eyes series win

by DigestWire member
November 16, 2025
0

"You don't come to a country to win a Test match, you obviously want to win the...

Glen Powell Flies UPS Driver to NYC to See Him Host ‘SNL’

Glen Powell Flies UPS Driver to NYC to See Him Host ‘SNL’

November 16, 2025
Trump’s Republican Party insists there’s no affordability crisis and dismisses election losses

Trump’s Republican Party insists there’s no affordability crisis and dismisses election losses

November 16, 2025
Nearly 70 schools to close in Australia over fears of asbestos in play sand

Nearly 70 schools to close in Australia over fears of asbestos in play sand

November 16, 2025
Arrest over deadly car blast in New Delhi

Arrest over deadly car blast in New Delhi

November 16, 2025
DIGEST WIRE

DigestWire is an automated news feed that utilizes AI technology to gather information from sources with varying perspectives. This allows users to gain a comprehensive understanding of different arguments and make informed decisions. DigestWire is dedicated to serving the public interest and upholding democratic values.

Privacy Policy     Terms and Conditions

Recent News

  • ‘Job’s far from done’ – Conrad eyes series win November 16, 2025
  • Glen Powell Flies UPS Driver to NYC to See Him Host ‘SNL’ November 16, 2025
  • Trump’s Republican Party insists there’s no affordability crisis and dismisses election losses November 16, 2025

Categories

  • Blockchain
  • Blog
  • Breaking News
  • Business
  • Cricket
  • Crypto Market
  • Cryptocurrency
  • Defense
  • Entertainment
  • Football
  • Founders
  • Health Care
  • Opinion
  • Politics
  • Sports
  • Strange
  • Technology
  • UK News
  • Uncategorized
  • US News
  • World

© 2020-23 Digest Wire. All rights belong to their respective owners.

No Result
View All Result
  • Home
  • World
  • UK
  • US
  • Breaking News
  • Technology
  • Entertainment
  • Health Care
  • Business
  • Sports
    • Sports
    • Cricket
    • Football
  • Defense
  • Crypto
    • Crypto News
    • Crypto Calculator
    • Blockchain
    • Coins Marketcap
    • Top Gainers and Loser of the day
    • Crypto Exchanges
  • Politics
  • Opinion
  • Strange
  • Blog
  • Founders
  • Contribute!

© 2024 Digest Wire - All right reserved.

Privacy Policy   Terms and Conditions

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.